Lundbeck to Present Broad Range of Data on Migraine and Brain Health at 75th Annual Meeting of the American Academy of Neurology
Lundbeck's Biologic Vyepti (Eptinezumab) Receives Approval in the U.S.
Vyepti failed to significantly outdo placebo at reducing monthly migraine days in a phase 3 trial called Sunlight, Lundbeck disclosed (PDF) Wednesday alongside its second-quarter financial results.
DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck today announced data on VYEPTI® (eptinezumab-jjmr) will be presented at the 64th Annual Scientific Meeting of the American Headache Society (AHS) taking place from June 9-12, 2022. A total of nine poster presentations will be shared to highlight clinical data and real-world analyses of eptinezumab as a preventive migraine treatment in adults.
Lundbeck`s Vyepti (Eptinezumab) Receives Approval in Europe
Lundbeck`s Biological Eptinezumab-Jjmr Receives Supplemental Approval In US
The full results from the RELIEF study were published today in The Journal of the American Medical Association (JAMA). VYEPTI® (eptinezumab-jjmr) met both co-primary endpoints, showing early benefit for time to headache pain freedom, and time to the absence of most bothersome symptoms (MBS), compared to placebo. Patients treated with VYEPTI experienced headache pain freedom and absence of their MBS at 2 hours post-infusion, achieving the key secondary endpoints. The RELIEF study evaluated how preventive migraine candidates may benefit from a VYEPTI infusion during an active migraine attack when administered within 1 to 6 hours of a moderate to severe migraine attack. VYEPTI is the first and only intravenous (IV) infusion approved for the preventive treatment of migraine in adults.
New Data Presented at 2021 American Academy of Neurology (AAN) Annual Meeting Shows VYEPTI® (eptinezumab-jjmr) Demonstrated Earlier Time to Freedom from Headache Pain and Absence of Most Bothersome Symptoms Compared to Placebo When Initiated During Migraine Attack in Patients Who Were Candidates for Preventive Therapy
 H. Lundbeck A/S (Lundbeck) today announced headline results from the parallel group, double-blind, randomized, placebo-controlled RELIEF study[i] that assessed the efficacy and tolerability of Vyepti when initiated during a migraine attack in patients who are candidates for preventive therapy. The study met statistical significance on the co-primary endpoints, demonstrating that patients receiving a 100 mg Vyepti infusion during a migraine attack achieved earlier time to freedom from headache pain and absence of their most bothersome symptom compared to patients receiving placebo. The most bothersome symptom was the individual patient's choice between photophobia, phonophobia, and nausea.